HCA Healthcare Beats Q1 EPS Estimates, Reaffirms Guidance, and Repurchases $1.57B in Shares
Summary
HCA Healthcare announced Q1 2026 results, beating EPS estimates, reaffirming its full-year guidance, and executing a substantial $1.57 billion share repurchase.
Key Events
-
Q1 Earnings Beat Expectations
HCA Healthcare reported diluted earnings per share of $7.15 for Q1 2026, surpassing analyst estimates of $7.00. Revenues increased 4.3% to $19.109 billion compared to the prior year.
-
Full-Year Guidance Reaffirmed
The company reaffirmed its previously issued 2026 estimated guidance ranges, maintaining its outlook for the full year despite a dynamic operating environment.
-
Significant Share Repurchases
During the first quarter of 2026, HCA Healthcare repurchased 3.157 million shares of its common stock at a cost of $1.571 billion, with $9.179 billion remaining under its authorization as of March 31, 2026.
-
Quarterly Dividend Declared
The Board of Directors declared a quarterly cash dividend of $0.78 per share, payable on June 30, 2026, to stockholders of record on June 16, 2026.
Analysis
HCA Healthcare reported first-quarter earnings that surpassed analyst expectations, demonstrating solid financial performance despite some operational headwinds. The company's diluted EPS of $7.15 exceeded estimates, and revenues also saw a healthy increase. The reaffirmation of its full-year 2026 guidance, originally issued on January 27, 2026, provides stability and confidence in its outlook. Furthermore, the significant repurchase of $1.571 billion in common stock during the quarter underscores the company's commitment to returning capital to shareholders and reflects strong cash flow generation. This substantial capital return, representing a notable portion of its market capitalization, is a strong positive signal.
At the time of this filing, HCA was trading at $437.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $106B. The 52-week trading range was $321.39 to $556.52. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.